An analyst's opinion of Merck's pharmaceutical strategy Merck's pharmaceutical strategy is entirely on track: The successful implementation of the "Fit for 2018" transformation and growth program is reflected in efficiency gains and the successful execution of growth initiatives as well as pipeline progress particularly in Immuno-Oncology and the Biosimilars business unit, among others. "pro" asked Peter Spengler, an analyst at DZ Bank in Frankfurt who closely follows the development of Merck with a critical eye, about how he assesses the recent development of Merck's pharmaceutical business.
